A Patient-Reported Outcome Measure of Communication Difficulties in Friedreich Ataxia: COMATAX

Area of Science:

• Neurology
• Speech-Language Pathology
• Patient-Reported Outcome Measures

Background:

• Friedreich ataxia (FA) progressively impairs communication, affecting speech, hearing, socio-cognitive, and language skills.
• There is a critical need to understand the multifaceted communication challenges faced by FA patients.
• The COMunication and ATAXia measure (COMATAX) was developed to address this gap.

Purpose of the Study:

• To develop and validate the COMunication and ATAXia measure (COMATAX) for assessing communication disabilities in Friedreich ataxia.
• To evaluate the reliability and validity of the COMATAX scale in a patient cohort.
• To establish COMATAX as a tool for use in clinical trials for FA.

Main Methods:

• Focus groups and cognitive interviews with FA patients, professionals, and caregivers informed item development.
• Validation involved 93 FA patients using a mobile health app, assessing distribution, reliability (Cronbach's alpha), and validity.
• Correlations with established scales (VHI-30, SSQ-12, SARA) and subgroup analyses were performed; Item Response Theory (IRT) was used.

Main Results:

• The COMATAX is a 17-item scale with an additional question on the most bothersome symptom.
• It demonstrated high internal consistency (α = 0.897) and strong correlations with VHI-30 (r=.894).
• The measure effectively distinguished between various patient subgroups based on disease severity and functional status.

Conclusions:

• The COMATAX is a validated and reliable patient-reported outcome measure for communication disability in FA.
• It is suitable for use in future therapeutic trials investigating treatments for Friedreich ataxia.
• COMATAX provides a crucial tool for quantifying communication deficits in FA research.